Veterinary Recombinant Biologics


Next Generation Biologics

In humans, therapeutic biologics have revolutionized the practice of medicine, providing more effective and safer treatments for many diseases including various cancers as well as inflammatory and autoimmune disorders.  KindredBio is focused on development of next generation veterinary therapeutic biologics, such as monoclonal antibodies and recombinant proteins, for our cats, dogs, and horses.

Monoclonal Antibodies

Monoclonal antibodies (mAb) are antibodies produced by identical cells cloned from a unique parent cell.  Monoclonal antibodies differ from polyclonal antibodies which are produced by several different types of cells. Monoclonal antibodies bind to a specific epitope on the targeted cell type or soluble target.

Monoclonal antibodies have become the gold standard for treatment of many human diseases because of their safety and efficacy profile, along with their high specificity and long half-life. Anti-inflammatory monoclonal antibodies which inhibit TNFα, such as Infliximab (Remicade®) and Adalimumab (Humira®), are widely used in the treatment of Crohn’s Disease, Ulcerative Colitis, and Rheumatoid Arthritis to name a few. Rituximab (Rituxan®), a monoclonal antibody to CD20 on B cells, is used for the treatment of non-Hodgkin’s lymphomas. Other monoclonal antibodies including Avastin® and Lucentis® are widely used for treatment of inflammatory and autoimmune disorders as well as cancer in human medicine.

Recombinant Proteins

Recombinant biologics are produced by inserting the genetic code for a specific therapeutic protein into the DNA of an expression vector in the laboratory.  The DNA codes for protein which are inserted into the genome result in production of large quantities of recombinant protein through replication in living host cells in the laboratory.  The recombinant protein produced is then purified and the final preparation administered to the animal (cat, dog, or horse) for targeted therapy.  Unlike non-recombinant proteins purified directly from serum of the animals, recombinant proteins are produced in a controlled and sterile environment resulting in a uniform product with control of viral and bacterial contamination. The final preparation (drug formulation) is sterile and contains a highly pure and targeted drug.

The Process

1 The process starts with identification and isolation of the genetic code for the desired therapeutic protein and inserting the genes of interest into the expression vector’s DNA.

2 The expression vector is double-stranded DNA capable of inserting itself into the host cell thereby introducing the genetic code of the therapeutic protein into the host cells.

3 The host cell produces recombinant protein along with host-cell proteins.

4 Recombinant protein is collected, separated, and purified from the host cell proteins and other components using conventional chromatography.

5 The final drug formulation is sterile and contains highly pure drug substance capable of binding to the specific epitope on the cell receptor or to a soluble target (such as cytokine).